MedWatch

Sanofi's big dermatology hope fails in phase III

One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.

Photo: Dado Ruvic/REUTERS / X02714

As things appear at the moment, Sanofi hasn't achieved its ambitions with drug rilzabrutinib that management had otherwise hoped when the French pharmaceutical company acquired the compound via its acquisition of Prinicipia Biopharma in 2020.

In any case, rilzabrutinib has showed itself to be a real fiasco within the field of dermatology. Here, the medication failed to pass its phase III trial as a treatment for two variants of the rare autoimmune skin disease pemfigus vulgaris and pemfigus foliaceus. The condition is characterized by blisters on skin and mucus membranes, sometimes leading to death among patients with compromised immune systems.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs